H eather A. Wakelee, MD, will become IASLC President shortly after WCLC 2021 ends although the ceremonial passing of the flag takes place on Thursday morning, 6:30 MDT. In 2020, Dr. Wakelee was promoted to Chief of the Division of Oncology at Stanford University. In early 2021 she became Deputy Director of the Stanford Cancer Institute. Dr. Wakelee has served the IASLC as Chair of the Communications Committee. Before WCLC 2021 started, Dr. Wakelee talked with WCLC Meeting News about her upcoming term and the opportunities and challenges the future holds for the IASLC and thoracic cancer care overall. Answers were edited for length and clarity. What goals do you have for the IASLC and your presidency in general? One of my main goals is going to be working to keep us all connected despite all of the global events that are keeping us physically apart. When we think about what the IASLC does, our focus is, of course, on conquering thoracic malignancies worldwide. But, in practicality, what we do is provide forums for people who care deeply CONQUERING THORACIC CANCERS WORLDWIDEWEDNESDAY, SEPTEMBER 8 INSIDE: PAGE 4 Preview of Plenary Sessions PAGE 6 Distinguished Award winners PAGE 11 Q&A: President-Elect Paul Van Schil PAGE 3 STARS program expands PAGE 14 List of 2021 exhibitors WCLC 2021: CONNECT AND COLLABORATE WITH COLLEAGUES FROM AROUND THE GLOBE Circumstances require a virtual plaform for this year’s meeting, but the IASLC remains committed to offering educational and engaging opportunities in the virtual space just as it has done over decades of in-person WCLCs. This year’s conference remains the premiere platform for presenting the latest science and serves as an example of the IASLC’s mission to provide critical thoracic cancer education to the largest, most diverse audience possible. Heather Wakelee, MD David Harpole, MD Both the Program and Regional Organizing committees have worked to ensure that meeting sessions are interdisciplinary and represent all specialties as much as possible. Planners talked with many member groups and meeting stakeholders to learn what worked from past conferences and to maximize the flexibility of the virtual environment regarding the timing and format of the sessions and forums. ... see WELCOME on page 15 WITH INCOMING IASLC PRESIDENT Q & A MAINTAINING CONNECTIONS IN TOUGH TIMES CRITICAL FOR IMPROVING THORACIC CANCER OUTCOMES ... see PRESIDENT on page 12 WELCOME TO THE IASLC 2021 WORLD CONFERENCE ON LUNG CANCER (WCLC). OUR COMMITMENT TO ONCOLOGY TODAY’S CLINICAL RESEARCH DEVELOPS HOPE FOR TOMORROW VV-OTHR-US-DEL-0521 04/2021 © Lilly USA, LLC 2021. All rights reserved.LOCATION STUDY TREATMENTS KEY ELIGIBILITY CRITERIA ASIA, AUSTRALIA, NORTH AMERICA RANDOMIZED, PHASE 2, OPEN-LABEL •Zimberelimab (anti-PD-1 antibody) •Domvanalimab(anti-TIGIT antibody)+ Zimberelimab •Domvanalimab + Zimberelimab + Etrumadenant (dual adenosine A 2a /A 2b receptor antagonist) NSCLC: •Histologically confirmed squamous or nonsquamous •PD-L1 positive •Metastatic •No EGFR or ALK mutations These molecules and their uses are investigational, have not been proven to be safe and effective, and have not been approved by any health authority. ASIA, EUROPE, LATIN AMERICA RANDOMIZED, PHASE 3, OPEN-LABEL •Zimberelimab •Chemotherapy •Domvanalimab + Zimberelimab NSCLC: •Histologically confirmed squamous or nonsquamous •Treatment-naive •PD-L1 positive •Locally advanced or metastatic •No EGFR or ALK mutations Do you have patients with NSCLC who could benefit from participating in an EXPLORE THE STUDIES AT arcusbio.com/clinical-trials/lung-cancer HAVE A PATIENT TO REFER? email us at clinicaltrials@arcusbio.com today! Arcus Biosciences, a company focused on precision combinations for cancer, is currently enrolling: ALK= anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer; PD-1=programmed death protein 1; PD-L1=programmed death ligand 1; TIGIT=T cell immunoreceptor with immunoglobulin and ITIM domain. © 2021 Arcus Biosciences, Inc. All rights reserved. Approved July 2021. ANTI-TIGIT CLINICAL TRIAL?WEDNESDAY, SEPTEMBER 8, 2021 | WORLDWIDE VIRTUAL EVENT3 S ince its inception in 2019 with five patient research advocates (PRAs), the Supportive Training for Advocates on Research and Science (STARS) program has grown quickly, but the mission remains the same. This year, STARS will have 15 PRAs from seven countries receiving training about the science and realities involved in lung cancer research. The STARS program, managed by the IASLC, has been developed specifically for the lung cancer community through collaboration with lung cancer patient advocates, PRAs, and advocacy organizations from several countries. Its design and content draw on the experiences and lessons learned from research advocate training programs for other types of cancer, such as Project LEAD (breast cancer), Research Advocacy Network’s Advocate Institute, and American Association of Cancer Research Scientist Survivor Program, and tailors that knowledge to the specific needs of the lung cancer community. “We have more and more patients, survivors, caregivers, and advocates attending medical conferences, and we want them to feel empowered and confident when viewing the scientific presentations and networking with researchers, scientists, and other members of care teams so they can speak the language and take that information back to either their support groups or avenues of advocacy that they are passionate about,” said Kristin Ito, Associate Director, ILC Foundation and Patient Advocacy for IASLC. The program brings the PRAs together with mentors from the lung cancer research community. For WCLC 2021, mentors will help the PRAs build an appropriate schedule of sessions to watch and provide tips on how to navigate and practice self-care during a virtual research conference. Although a critical part of the training, WCLC 2021 is just one part of an extended learning period for the STARS-in-training. Throughout the 4-month program, STARS participants will learn from several experts about the latest science topics and communication skills to share that scientific information clearly to a broad audience. In addition, through a partnership with the Research Advocacy Network (RAN), participants will use online modules for an improved self- study experience, following with STARS-facilitated online group discussions with fellow PRAs-in- training and mentors. In addition to the Research Advocacy Network Advocate Institute, STARS works with LUNGevity and GO2 Foundation for Lung Cancer. More details about the program are available at iaslc.org under the “Patient Advocacy” tab. STARS PROGRAM CONTINUES TO EXPAND, TRAIN MORE PATIENT RESEARCH ADVOCATES Aliye Bricker United States “STARS means opening the door for more patients to find a comfort level with research advocacy, allowing for more meaningful collaborations between the patient community and the scientific community. I look forward to building on my knowledge and gaining the confidence to serve more effectively as a lung cancer advocate.” Sarah Christ United States Seamus Cotter Ireland “The STARS program means having a patient voice in changes being made in the field. There is no better voice than the patients who take the treatments.” Tiffany Fagnani United States Leslie LaChance United States “Palliative care needs to begin from Day One of being diagnosed with cancer. It is equally important to relieve mental suffering along with physical suffering.” Nabanita Mandal India Jacquelyn Nixon United States “Being in the STARS program will provide me with a better understanding of radon and its effects on incidence of lung cancer. By telling my story and adding the STARS education to it, l will be able to more effectively drive home the reasons why I survived and let folks know that they have a lot of control over their outcomes.” Stella O’Brien United Kingdom Korina Pateli-Bell Greece Angus Pratt Canada Andrea Redway Canada Mike Smith United States “As a STARS Patient Research Advocate, I hope to make a difference no matter how great or small to change the narrative of lung cancer.” Baerbel Soehlke Germany Diane Van Keulen Canada Wayne Yeung United States “It has become clear to me that there is almost no active, lung-specific advocacy currently in my country. Since engaging with researchers in Ireland, I have found that there are many opportunities for patient input to research and I would love to lead the way as the first PRA in Ireland to complete the STARS program.” “I am fascinated by the lung cancer that is killing me. It has been a steep personal learning curve. I am hoping that the STARS structured learning program will fill in blanks in my knowledge and strengthen my ability to advocate as a patient in research.” 2021 STARS PATIENT RESEARCH ADVOCATES4IASLC WORLD CONFERENCE ON LUNG CANCER | #WCLC21 THE PRESIDENTIAL SYMPOSIUM at WCLC will once again highlight the latest groundbreaking science. Moderated by the Outgoing IASLC President Tetsuya Mitsudomi, MD, PhD, and WCLC 2021 Conference Chair David Harpole, MD, the Presidential Symposium will showcase five important studies dealing with thoracic malignancies. It will take place 06:30–08:00 MDT on Thursday, Sept. 9, with a second broadcast taking place 14:30–16:00 MDT. The Presidential Symposium will include results from the POSEIDON, ATLANTIS, and IMpower010 clinical trials, as well as a study about lung cancer and air pollution. An IASLC study of how COVID-19 has impacted lung cancer clini- cal trials globally and currently used mitigation strategies also is included. This year’s Presidential Symposium will be the second of five plenary sessions on the schedule. The first, on Wednesday, Sept. 8, 07:00–08:00 MDT, will examine disparities in thoracic oncology. Journal of Thoracic Oncology (JTO), Editor-in-Chief Alex A. Adjei, MD, and Raymond Uyiosa Osarogiagbon, MD, Baptist Cancer Center, Memphis, Tenn., will speak to the critical disparities in both diagnosis and treatment. “This is such an important topic across the world,” said WCLC 2021 Co-Chair Kristin Higgins, MD. “We have some great thought leaders that are going to be giving presentations that should inspire us about ways that we can take action and reach patients whom we have not been able to reach before with therapies.” The final three plenary sessions have been scheduled for various times so as to allow convenient access to the information around the globe. The Sunday, Sept. 12, plenary takes place 16:15–17:15 MDT and will update attendees on the current state and future directions for screening around the world, with presentations covering many regions. On Tuesday, Sept. 14, 16:15–17:15 MDT, plenary speakers will consider stigma as a risk factor for disease. The plenaries conclude with a session also on Sept. 14, 21:15–22:15 MDT, looking into the future of immunotherapy and other novel therapies. All plenary sessions will have translations available in Japanese, Mandarin, and Spanish. “We are looking forward to all of the plenary sessions, for which we have chosen broad themes such as disparities of care and immunotherapy and resectable disease, as well as other topics that are very important to thoracic oncologists. These topics are in addition to the Presidential Symposium, which will provide some new data from studies,” said WCLC 2021 Co-Chair Thomas A. Stinchcombe, MD. PRESIDENTIAL SYMPOSIUM, EXAMINATION OF DISPARITIES IN THORACIC ONCOLOGY PART OF STRONG PLENARY PROGRAM PLENARY SCHEDULE (ALL TIMES MDT) All plenary sessions will have translations available in Japanese, Mandarin, and Spanish. PL01 - Opening Plenary: Access and Disparities Sept. 8 | 07:00 - 08:00 Moderators: Lucia Zatarain Barron, Tetsuya Mitsudomi PL01.01 - Introduction and IASLC Award Presentations Presenter: Tetsuya Mitsudomi, Lucia Zatarain Barron PL01.02 - Disparities in Lung Cancer Care Across the Population Presenter: Raymond Uyiosa Osarogiagbon PL01.03 - Disparities in Lung Cancer Care: The Global Burden Presenter: Alex Adjei PL01.04 - Live Discussion with Speakers PL02 - Plenary 2: Presidential Symposium Sept. 9 | 06:30 - 08:00 Moderators: David Harpole, Tetsuya Mitsudomi PL02.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study Presenter: Melissa L Johnson; Discussant: Julie Brahmer PL02.03 - Lurbinectedin/ Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial Presenter: Luis Paz-Ares; Discussant: Charles M. Rudin PL02.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab Presenter: Nasser Altorki; Discussant: Ichiro Yoshino PL02.07 - Global Variability in Lung Cancer Deaths Attributable to Air Pollution Presenter: Christine Dorothy Berg; Discussant: Joachim G.J.V. Aerts PL02.09 - International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials Presenter: Matthew Smeltzer; Discussant: Marina Chiara Garassino PL02.11 - Live Discussion with Speakers PL02A - Plenary 2: Presidential Symposium (Rebroadcast) Sept. 9 | 14:30 - 16:00 PL03 - Plenary 3: Screening: The Global Landscape, Progress, and Future Directions Sept. 12 | 16:15 - 17:15 Moderators: Karen Canfell, Ella Kazerooni PL03.01 - Lung Cancer Screening in Europe: Current Status Presenter: Ugo Pastorino PL03.02 - Lung Cancer Screening in Latin America: Current Status and Challenges Presenter: Ricardo Santos PL03.03 - Lung Cancer Screening in Asia Presenter: Li Fan PL03.04 - Radiomics in Lung Cancer Radiation Treatment Assessment: Recent Progress and Future Directions Presenter: Fang-Fang Yin PL03.05 - Live Discussion with Speakers PL04 - Plenary 4: Stigma as Risk Factor: Why You Should Care Sept. 14 | 16:15 - 17:15 Moderators: Heather Wakelee, Merel Hennink PL04.01 - The Collective Perspective from Patients/ Families with an Untold Story and Foresight for What Is Needed Presenter: Jill Feldman PL04.02 - Lay Groundwork, Extent of the Problem, Why You Should Care and Discuss Strategic Framework of NLCRT Stigma Task Force: Multi Stakeholder and Multidisciplinary Effort to Address and Eliminate Stigma Presenter: Jamie Studts PL04.03 - Talk About Solutions: Empathic Communication Module, Language Guide, Projects and Deliverables in Stigma with Attention to the Intersection of Patients, Clinicians and Researchers Presenter: Jamie Ostroff, Smita Banerjee PL04.04 - Psychological Distress and Stigma for People with Lung Cancer: Time to Act Presenter: Suzanne Chambers PL04.05 - Stigma as Risk Factor - Why You Should Care Presenter: Kazuo Hasegawa PL04.06 - ‘I Didn’t Smoke’ Language and Stigma Surrounding Lung Cancer (Personal Experience) Presenter: Gina Hollenbeck PL04.07 - Live Discussion with Speakers PL05 - Plenary 5: Closing Plenary: Immunotherapy and Beyond: Future Directions Sept. 14 | 21:15 - 22:15 Moderators: Silvia Novello, Thomas E. Stinchcombe PL05.01 - CAR T-cell Therapy for Thoracic Cancers Presenter: Prasad Adusumilli PL05.02 - Resistance/ Biology Presenter: Kurt Schalper PL05.03 - Radiation/ IO Synergy/Evolving Technology Presenter: Ken Harada PL05.04 - IO in the Surgical Resectable Patient Presenter: Jamie Chaft PL05.05 - Live Discussion with Speakers PL05.06 - Closing Remarks PL01 WED • SEPT 8 PL02 THURS • SEPT 9 PL02 (REPEAT) THURS • SEPT 9 PL03 SUN • SEPT 12 PL04 TUES • SEPT 14 PL05 TUES • SEPT 14 San Francisco 6:00–7:00 PDT5:30–7:00 PDT13:30–15:00 PDT15:15–16:15 PDT15:15–16:15 PDT20:15–21:15 PDT Denver 7:00–8:00 MDT6:30–8:00 MDT14:30–16:00 MDT16:15–17:15 MDT16:15–17:15 MDT21:15–22:15 MDT New York9:00–10:00 EDT8:30–10:00 EDT16:30–18:00 EDT18:15–19:15 EDT18:15–19:15 EDT23:15–0:15* EDT Rome 13:00–14:00 UCT12:30–14:00 UCT20:30–22:00 UCT22:15–23:15 UCT22:15–23:15 UCT3:15*–4:15* UCT Singapore 21:00–22:00 SGD20:30–22:00 SGD4:30*–6:00* SGD6:15*–7:15* SGD6:15*–7:15* SGD11:15*–12:15* SGD Sydney23:00–0:00* AEST22:30–0:00* AEST6:30*–8:00* AEST8:15*–9:15* AEST8:15*–9:15* AEST13:15*–14:15* AEST WCLC 2021 PLENARY TIMES Keeping the needs of the worldwide audience in mind, WCLC organizers have staggered the start times of the plenaries during WCLC 2021. View the full meeting program at wclc2021.iaslc.org/ program-at-a-glance/. *indicates next day Kristin Higgins, MD Thomas A. Stinchcombe, MDDo you have a plan to test for RET ? Ensure your testing methods include RET Consider NGS for your patients Retevmo ® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Other product/company names mentioned herein are the trademarks of their respective owners. PP-SE-US-0786 08/2021 © Lilly USA, LLC 2021. All rights reserved. NGS=next-generation sequencing; RET=rearranged during transfection. VISIT RETEVMO.COM/TEST TO LEARN MORE ABOUT TESTING METHODS FOR THIS ACTIONABLE BIOMARKERWINNERS OF THE DISTINGUISHED AWARDS 6IASLC WORLD CONFERENCE ON LUNG CANCER | #WCLC21 ADI F. GAZDAR IASLC MERIT AWARD: PROFESSOR MICHAEL BOYER, MBBS, FRACP, PHD PROFESSOR Michael Boyer, MBBS, FRACP, PhD, is a medical oncologist at Chris O’Brien Lifehouse, where he also holds the position of Chief Clinical Officer. He also is the Kam Ling Barbara Lo Chair in Lung and Thoracic Cancer at the Central Clinical School, University of Sydney. Professor Boyer has 30 years of experience in the management of thoracic malignancies and head and neck cancers. His major research interest is in clinical trials of new agents in the management of lung cancer, mesothelioma, and head and neck cancers. He played an integral role in the development and construction of the Chris O’Brien Lifehouse, a purpose- built cancer hospital, and joined the staff on its opening in 2013. In addition to his clinical roles, he has held senior administrative positions during that time including Head of Department of Medical Oncology at Royal Prince Alfred Hospital, Director of the Sydney Cancer Centre, and Area Director of Cancer Services for the Sydney Southwest Area Health Service. He was on the senior staff of the Sydney Cancer Centre and Royal Prince Alfred Hospital from 1993 to 2013. In 2010 he was made a Member of the Order of Australia for his work as an educator and a clinical trials researcher, as well as for his involvement in the development of integrated care facilities for people suffering with cancer. He is the author of more than 180 publications. Following his specialty training in medical oncology at Royal Prince Alfred and Westmead Hospitals, in Sydney, Professor Boyer was a Research Fellow and Clinical Fellow at the Ontario Cancer Institute and Princess Margaret Hospital in Toronto, Canada, where he completed his doctorate in cell biology. The Adi F. Gazdar IASLC Merit Award recognizes and honors Dr. Gazdar’s lifelong dedication to lung cancer research through his pioneering work in molecular pathology. JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD: GABRIELLA SOZZI, PHD GABRIELLA Sozzi, PhD, leads the Tumor Genomics Unit at Fondazione IRCCS Istituto Nazionale Tumori (INT) in Milan, Italy. Dr. Sozzi’s research centers on all aspects of lung cancer by using an integrated approach that combines cellular and molecular biology, biochemistry, and pharmacology to gain new insights in the pathogenesis of lung cancer and on novel ways to provide early diagnosis and treatment options. The goal of her translational studies is the implementation of highly sensitive molecular tests that could be used within screening programs to improve both detection and clinical management of lung cancer. She received a Junior Investigator Award for Excellence (IASLC), IASLC Award for Presidential Plenary Session, and the Award for Excellence in Medicine from the American-Italian Foundation for Cancer Research (AICF) in 2002. She has been an associate editor of the Journal of Thoracic Oncology since 2012, and she is a member of the IASLC Early Detection and Screening Committee. A past President of the Italian Cancer Society (SIC), Dr. Sozzi sits on scientific advisory boards of AICF and Associazione Italiana Ricerca Cancro (AIRC). She coordinates research in primary and secondary prevention and early detection for the Italian Ministry of Health at INT Milan and has authored or co- authored 245 full articles. She graduated in biological sciences from the University of Milan, received her doctorate in medical genetics at University of Pavia and trained in cancer genetics at Memorial Sloan Kettering in New York and at Thomas Jefferson University in Philadelphia. The Joseph W. Cullen Prevention/ Early Detection Award recognizes an IASLC scientist for a lifetime achievement in the prevention of thoracic malignancies. PAUL A. BUNN JR. SCIENTIFIC AWARD: DAVID P. CARBONE, MD, PHD DAVID CARBONE, MD, PhD, is a professor of internal medicine and director of the James Thoracic Oncology Center at the Ohio State University Comprehensive Cancer Center. He is also the Barbara J.Bonner Chair in Lung Cancer Research there. Dr. Carbone’s research interests have been focused on lung cancer and specifically proteomic and expression signature development, lung cancer genetics, tumor- associated immunosuppression mechanisms, proteogenomic profiling of lung cancers to guide the development of novel therapeutics and targeting novel immunosuppression mechanisms. He is a past president of the IASLC and the current chair of the Lung Biology Subcommittee for the Eastern Cooperative Oncology Group. He was recruited to The Ohio State University in 2012 to direct the James Thoracic Oncology Center. Before arriving in Ohio, he was director of the Thoracic/ Head and Neck Cancer Program and director of a SPORE in lung cancer for 11 years at Vanderbilt University. Dr. Carbone has more than 250 peer-reviewed publications, has served on the Board of Scientific Counselors, and has had continuous National Cancer Institute funding since early in his career. He graduated summa cum laude from Amherst College in 1977 and received a medical degree and doctorate in molecular biology and genetics at Johns Hopkins University in 1985. After an Internal Medicine internship and residency at The Johns Hopkins Hospital, he did a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. The Paul A. Bunn, Jr. Scientific Award recognizes an IASLC scientist for a lifetime achievement of scientific contributions to thoracic cancer research. MARY J. MATTHEWS PATHOLOGY/ TRANSLATIONAL RESEARCH AWARD: DEEPALI JAIN, MD, DNB, MNAMS, MNASI, FIAC DEEPALI JAIN, MD, DNB, MNAMS, MNASI, FIAC, works as additional professor in the Department of Pathology at All India Institute of Medical Sciences (AIIMS), New Delhi, India. Her current research focuses on thoracic malignancies, mostly lung cancer. She examines molecular biomarkers involved in the pathogenesis and pathology of non-small cell and small cell lung cancers in ethnically different and diverse population of patients in India. Dr. Jain’s areas of special interest are thoracic pathology and cytopathology, and she serves on the IASLC Pathology Committee and is a member of the ILCN Editorial Group. Dr. Jain has authored or co-authored more than 300 peer-reviewed articles and multiple book chapters, and she has received numerous distinguished national and international scientific awards. She is an editorial board member of 2021 World Health Organization (WHO) Classification of Thoracic Tumors and upcoming International System for Reporting Lung Cytopathology by IAC-IARC, First edition. She also is a member of International Collaboration on Cancer Reporting (ICCR), Thymic Epithelial Tumours dataset authoring committee. She also serves as an editor of Atlas of Thymic Pathology, First Edition. She is trained in pathology from Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The Mary J. Matthews Pathology/ Translational Research Award recognizes a scientist for a lifetime achievement in pathology and translational research of thoracic malignancies. WCLC 2021 LECTURESHIP AWARDS NOMINATING COMMITTEE AWARDS (Nominating Committee Chair: Giorgio Scagliotti, MD) DANIEL C. IHDE LECTURESHIP AWARD FOR MEDICAL ONCOLOGY Fabrice Barlesi, MD, PhD, France, Pulmonary Medicine: Prof. Barlesi is noted for his continuous support of IASLC activities, including his role as Associate Editor of the IASLC Lung Cancer News. HEINE H. HANSEN LECTURESHIP AWARD FOR SMALL CELL LUNG CANCER Trudy Oliver, PhD, United States, Pharmacology and Cancer Research: Dr. Oliver is a researcher who has delivered impactful contributions through her work on small-cell lung cancer. NURSES AND ALLIED HEALTH PROFESSIONALS AWARD (Nurses and Allied Health Professionals Committee Chair: Melissa Culligan, RN, MS) IASLC LECTURESHIP AWARD FOR NURSES AND ALLIED HEALTH PROFESSIONALS Pippa Labuc, BSc, OT, United Kingdom, Occupational Therapy: Ms. Labuc specializes in thoracic oncology, with a special interest in symptom management and rehabilitation for patients with an oncology/hematology diagnosis. RADIATION ONCOLOGY AWARD (Advance Radiology Technology Committee Chair: Corinne Fairve-Finn, FRCR, MD, PhD) JAMES D. COX LECTURESHIP AWARD FOR RADIATION ONCOLOGY Cecile Le Pechoux, MD, Villejuif, France, Radiation Oncology: A clinician who has made significant contributions to lung cancer research, Dr. Le Pechoux is widely recognized as a key opinion leader in thoracicradiation oncology. TOBACCO CONTROL AND SMOKING CESSATION AWARD (Tobacco Control and Smoking Cessation Committee Chair: Matthew Steliga, MD) IASLC LECTURESHIP AWARD FOR TOBACCO CONTROL AND SMOKING CESSATION Graham Warren, MD, PhD, United States, Radiation Oncology: Dr. Warren has dedicated his career to addressing the intersection of tobacco use and cancer, improving the health and quality of life for those who have fallen victim to tobacco-use disorder. PATHOLOGY COMMITTEE AWARD (Pathology Committee Chair: Keith Kerr, BSc, MB ChB, FRCPath, FRCPE) FRED R. HIRSCH LECTURESHIP AWARD FOR TRANSLATIONAL RESEARCH (INAUGURAL YEAR) Lynette Sholl, MD, United States, Pathology: Dr. Sholl’s extensive research focuses on identifying pathologic, immunohistochemical, and genetic markers in lung cancer. STAGING AWARDS (Staging Committee Chair: Hisao Asamura, MD) ROBERT J. GINSBERG LECTURESHIP AWARD FOR SURGERY Shun-ichi Watanabe, MD, PhD, Japan, Thoracic Surgery: Dr. Watanabe’s specializes in performing sublobar resection, lymph node dissection, and extended resection. CLIFTON F. MOUNTAIN LECTURESHIP AWARD FOR STAGING Ayten K. Cangir, MD, Turkey, Cardiothoracic Surgery: Dr. Cangir is engaging her local network in the creation of IASLC staging database and conducting a study on radiomics signature as a predictive factor for EGFR mutations in lung adenocarcinoma. TSUGUO NARUKE LECTURESHIP AWARD FOR SURGERY James Huang, MD, USA, Thoracic Surgery: Dr. Huang is involved with the refinement of the nodal staging system for the 8th Edition of the TNM Classification for Thoracic Cancers. WEDNESDAY, SEPTEMBER 8, 2021 | WORLDWIDE VIRTUAL EVENT7 IASLC.org/IASLC-News IASLC Lung Cancer News › The ILCN, the IASLC’s official newspaper, has transitioned to an all-digital platform on IASLC.org. › More timely and relevant lung cancer news. More nuanced expert perspectives about clinical care. › More global and multidisciplinary content › Easily discoverable and there when you need it. The Official Newspaper of the IASLC 2021 World Conference on Lung Cancer WCLC 2021 Meeting News is published by the International Association for the Study of Lung Cancer (IASLC). IASLC Headquarters is located at 999 17th Street, Suite 200, Denver, Colorado 80202-2725, USA Disclaimer: The ideas and opinions expressed in WCLC 2021 Meeting News do not necessarily reflect those of the IASLC. The mention of any product, service or therapy in this publication should not be construed as an endorsement, and the Association accepts no responsibility for any injury or damage to person or persons arising from or related to any use of material contained in this publication or to any errors or omissions. TriStar Event Media, LLC 7285 West 132nd Street, Suite 300, Overland Park, Kansas 66213 | www.tristareventmedia.com WCLC MEETING NEWS #WCLC21Reference: COSELA (trilaciclib). Prescribing Information. G1 Therapeutics, Inc; 02/2021. G1 Therapeutics™ and the G1 Therapeutics logo, COSELA™ and the COSELA logo are trademarks of G1 Therapeutics, Inc. ©2021 G1 Therapeutics, Inc. All rights reserved. US-2100258 07/2021 SPARE THE MARROW. COSELA HELPS PROTECT AGAINST MYELOSUPPRESSION, PROACTIVELY HELP PROTECT AGAINST MULTIPLE MYELOSUPPRESSIVE CONSEQUENCES WITH THE FIRST AND ONLY MYELOPROTECTION THERAPY The Pivotal Study (Study 1) compared an etoposide/carboplatin + atezolizumab (E/P/A) regimen with COSELA vs without COSELA* To decrease the incidence of chemotherapy-induced myelosuppressionin patients when administered prior to a platinum/ etoposide-containing regimen or topotecan-containing regimen FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) COSELA™ (trilaciclib) helps protect hematopoietic stem and progenitor cells (HSPCs), the source of blood cell lineages INDICATION COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). * COSELA was evaluated in 3 randomized, double-blind, placebo-controlled clinical studies. The Pivotal Study (Study 1) evaluated COSELA or placebo administered prior to treatment with E/P/A in 107 patients with newly diagnosed ES-SCLC not previously treated with chemotherapy. In this study, COSELA significantly reduced the primary endpoints of incidence (adjusted relative risk [aRR] 0.038 [95% CI, 0.008, 0.195], P<0.0001) and duration in Cycle 1 (mean difference -3.6 [95% CI, -4.9, -2.3], P<0.0001) of severe neutropenia and significantly decreased the rate of all-cause chemotherapy dose reductions (aRR 0.242 [95% CI, 0.079, 0.742]). The incidence of Grade 3/4 anemia was 19% and 28% (aRR 0.663 [95% CI, 0.336, 1.310]) and RBC transfusions on/after 5 weeks were 13% and 21% (aRR 0.642 [95% CI, 0.294, 1.404]) with and without COSELA, respectively. VISIT COSELA.COM FOR MORE DETAILSTo report suspected adverse reactions, contact G1 Therapeutics at 1-800-790-G1TX or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. This information is not comprehensive. Please see the Brief Summary of Prescribing Information on the adjacent page. SPEAR THE TUMOR. WHILE CHEMOTHERAPY TARGETS CANCER CELLS SELECT IMPORTANT SAFETY INFORMATION CONTRAINDICATION • COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib. WARNINGS AND PRECAUTIONS Injection-Site Reactions, Including Phlebitis and Thrombophlebitis • COSELA administration can cause injection-site reactions, including phlebitis and thrombophlebitis, which occurred in 56 (21%) of 272 patients receiving COSELA in clinical trials, including Grade 2 (10%) and Grade 3 (0.4%) adverse reactions. Monitor patients for signs and symptoms of injection-site reactions, including infusion-site pain and erythema during infusion. For mild (Grade 1) to moderate (Grade 2) injection-site reactions, flush line/cannula with at least 20 mL of sterile 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP after end of infusion. For severe (Grade 3) or life-threatening (Grade 4) injection-site reactions, stop infusion and permanently discontinue COSELA. Injection-site reactions led to discontinuation of treatment in 3 (1%) of the 272 patients. Acute Drug Hypersensitivity Reactions • COSELA administration can cause acute drug hypersensitivity reactions, which occurred in 16 (6%) of 272 patients receiving COSELA in clinical trials, including Grade 2 reactions (2%). Monitor patients for signs and symptoms of acute drug hypersensitivity reactions. For moderate (Grade 2) acute drug hypersensitivity reactions, stop infusion and hold COSELA until the adverse reaction recovers to Grade ≤1. For severe (Grade 3) or life-threatening (Grade 4) acute drug hypersensitivity reactions, stop infusion and permanently discontinue COSELA. Interstitial Lung Disease/Pneumonitis • Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin- dependent kinases (CDK)4/6 inhibitors, including COSELA, with which it occurred in 1 (0.4%) of 272 patients receiving COSELA in clinical trials. Monitor patients for pulmonary symptoms of ILD/pneumonitis. For recurrent moderate (Grade 2) ILD/ pneumonitis, and severe (Grade 3) or life-threatening (Grade 4)ILD/pneumonitis, permanently discontinue COSELA. Embryo-Fetal Toxicity • Based on its mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use an effective method of contraception during treatment with COSELA and for at least 3 weeks after the final dose. ADVERSE REACTIONS • The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia. Only approved for use in the US.Next >